Dosing Guidance Lacking For Leading COVID-19 Antiviral Therapies, ASHP Analysis Shows
Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir.
You may also be interested in...
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.
Unlike diagnostics, EUAs for drugs are rare and the fact that there already are FDA-approved competitors for Bayer’s chloroquine phosphate product may make the decision more complicated.
First COVID-19 experimental treatment trial in US is a master protocol that echoes NIH’s Ebola treatment approach.